Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer

[1]  S. Steinberg,et al.  Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Amiji,et al.  Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice. , 2013, Molecular Pharmaceutics.

[3]  D J Cole,et al.  Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy , 2013, Cancer Gene Therapy.

[4]  Jing Xu,et al.  Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles , 2012, Journal of visualized experiments : JoVE.

[5]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[6]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Couvreur,et al.  Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine , 2009, Journal of drug targeting.

[8]  E. O’Reilly,et al.  Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer , 2009, Cancer Gene Therapy.

[9]  D. Green,et al.  Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.

[10]  C. Unger,et al.  Antimetastatic Effects of Liposomal Gemcitabine and Empty Liposomes in an Orthotopic Mouse Model of Pancreatic Cancer , 2009, Pancreas.

[11]  E. O’Reilly.  Pancreatic adenocarcinoma: new strategies for success. , 2009, Gastrointestinal cancer research : GCR.

[12]  Mansoor Amiji,et al.  Epidermal Growth Factor Receptor-Targeted Gelatin-Based Engineered Nanocarriers for DNA Delivery and Transfection in Human Pancreatic Cancer Cells , 2008, The AAPS Journal.

[13]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[14]  P. Bycott,et al.  Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study , 2008, The Lancet.

[15]  D. Mukhopadhyay,et al.  Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. , 2008, Cancer research.

[16]  D. Tait,et al.  Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy , 2007, British Journal of Cancer.

[17]  M. Amiji,et al.  Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[18]  M. Amiji,et al.  Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. , 2007, Journal of pharmaceutical sciences.

[19]  Eileen M O'Reilly,et al.  Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Amiji,et al.  Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. , 2005, Bioconjugate chemistry.

[22]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Lowe,et al.  Control of apoptosis by p53 , 2003, Oncogene.

[25]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Friess,et al.  Acquired Resistance of Pancreatic Cancer Cells towards 5-Fluorouracil and Gemcitabine Is Associated with Altered Expression of Apoptosis-Regulating Genes , 2002, Oncology.

[27]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[28]  D. Hedley,et al.  Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. , 2000, Cancer research.

[29]  M. Cascalló,et al.  Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer , 2000, Cancer Gene Therapy.

[30]  J. Carretero,et al.  Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. , 1999, Free radical biology & medicine.

[31]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[32]  P. Hall,et al.  Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. , 1991, British Journal of Cancer.

[33]  M. Amiji,et al.  Preparation and loading of gelatin nanoparticles. , 2008, CSH protocols.

[34]  M. Amiji,et al.  Intracellular trafficking studies using gold-encapsulated gelatin nanoparticles. , 2008, CSH protocols.

[35]  M. Amiji,et al.  Cell Transfection and Analysis Using DNA-Loaded Gelatin Nanoparticles. , 2008, CSH protocols.

[36]  R. Moats,et al.  Assessing growth and response to therapy in murine tumor models. , 2005, Methods in molecular medicine.

[37]  Leila Mohammadi,et al.  BMC Cancer , 2001 .